Table 1: Relative risk of association between T2D and cancer, as reported by meta-analysis studies.

CancerNumber of examined studiesRelative risk (CI 95%)Reference number

LiverCase control 2.50 (1.80–3.50)[81]
Cohort ( )2.51 (1.90–3.20)[81]
Cohort ( )2.01 (1.61–2.51)[82]

EndometriumCase-control ( )2.22 (1.80–2.74)[83]
Cohort ( )1.62 (1.21–2.16)[83]

PancreasCase-control ( )1.94 (1.53–2.36)[84]
Cohort ( )1.73 (1.59–1.88)[84]
Case-control ( )1.80 (1.50–2.10[85]
Cohort ( )1.94 (1.66–2.27)[86]

KidneyCohort ( )1.42 (1.06–1.91)[87]

Biliary tractCase-control ( ) and cohort ( )1.43 (1.18–1.72)[88]
Case-control ( ) and cohort ( )1.60 (1.38–1.87)[89]

BladderCase-control ( )1.37 (1.04–1.80)[90]
Cohort ( )1.43 (1.18–1.74)[90]

Colon-rectumCase-control ( )1.36 (1.23–1.50)[91]
Cohort ( )1.29 (1.16–1.43)[91]
Case-control + cohort ( )1.38 (1.26–1.51)[92]

EsophagusCase-control ( ) and cohort ( )1.30 (1.12–1.50)[93]

N-H lymphoma*Case-control ( )1.12 (0.95–1.31)[94]
Cohort ( )1.41 (1.07–1.88)[94]
Case-control ( )1.18 (0.99–1.42)[95]
Cohort ( )1.79 (1.30–2.47)[95]

BreastCase-control ( )1.18 (1.05–1.32)[96]
Cohort ( )1.20 (1.11–1.30)[96]

* Non-Hodgkin’s lymphoma.